CBIA Canopus Biopharma Inc (PK)

Drake Holding Corp. (DRKH.PK) announced that its corporate name has been officially changed to Canopus BioPharma, Inc. and, to reflect the new name, that its ticker symbol has been changed to CBIA. The ticker symbol change for Canopus BioPharma (CBIA.PK), approved by the NASD, was effective at the commencement of trading today, July 16, 2007. As previously announced, Canopus BioPharma consummated a reverse merger and Stock Purchase Agreement to become a publicly traded operating company. Accompanying these transactions, Leo Prendergast, Patrick Prendergast and Len Rothstein were elected to the Company�s Board of Directors. The Prendergasts are brothers and are also executive officers of Canopus BioPharma. In addition, the Company�s Board of Directors and shareholders voted to effectuate a 1 for 15 �reverse split� of the outstanding common shares, resulting in approximately 9,120,000 shares currently outstanding. The Company is involved in the development and commercialization of products related to novel pharmaceuticals in the areas of antivirals, radiation protection, cancer therapies, camelidae blood products and bio-barcode assay technologies. Prior to establishing the strategic direction for the biopharmaceutical research and development at Canopus BioPharma, the Prendergasts were instrumental in creating the science that drove Hollis-Eden Pharmaceuticals, Inc (Nasdaq: HEPH) to a market value which reached at its height approximately $500 million. Canopus BioPharma is leveraging the Prendergasts� collective experience in biotechnology research and development spanning in excess of 50 years as well as the Company�s scientific and laboratory partnerships on five continents. Canopus BioPharma, Inc. (CBIA.PK) is dedicated to providing the safest, most cost effective and efficacious pharmaceutical products and assay methods to patients suffering from infectious disease, chemical warfare, cancer, and addiction. With innovative science, proven research and development leadership, and superior products and compounds, Canopus BioPharma has since 2001 been committed to becoming a market trend setter in the new era of healthcare, which is focused on providing affordable therapeutic benefit and pharmaceutical excellence to patients and healthcare professionals worldwide. In addition, the Company is a world leader in the development of novel camelid antibody products to provide unique avenues of progress and improvement in assay methods and monitoring capabilities for physicians, patients and researchers. Canopus maintains staff in Australia, South Africa, Ireland and the USA. Additional information on the Company is available at www.canopusbiopharma.com. With the exception of historical information contained in this press release, content herein may contain �forward looking statements� that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management�s current expectations and are subject to uncertainty and changes in circumstances. In particular, the Company may not be successful in its efforts commercialize or attain acceptable clinical results for its products. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts and research and development programs, uncertainties as a result of research and development, consumer and industry acceptance, litigation and/or court proceedings, regulatory risks including approval of Food and Drug Administration filings, the ability to achieve and maintain revenues and profitability in the Company�s business lines, and other factors discussed in the Company's filings with the Securities and Exchange Commission.